The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of VYNE Therapeutics Inc (NASDAQ: VYNE) closed at $0.32 in the last session, up 5.19% from day before closing price of $0.3. In other words, the price has increased by $5.19 from its previous closing price. On the day, 1.71 million shares were traded. VYNE stock price reached its highest trading level at $0.32 during the session, while it also had its lowest trading level at $0.295.
Ratios:
We take a closer look at VYNE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.60 and its Current Ratio is at 7.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 15 ’25 when LEPORE PATRICK G bought 15,000 shares for $2.92 per share. The transaction valued at 43,800 led to the insider holds 51,472 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYNE now has a Market Capitalization of 8151093 and an Enterprise Value of -31470908. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.98 while its Price-to-Book (P/B) ratio in mrq is 0.16. Its current Enterprise Value per Revenue stands at -66.115.
Stock Price History:
The Beta on a monthly basis for VYNE is 1.90, which has changed by -0.82608694 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, VYNE has reached a high of $4.30, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is -43.42%, while the 200-Day Moving Average is calculated to be -80.18%.
Shares Statistics:
According to the various share statistics, VYNE traded on average about 2.39M shares per day over the past 3-months and 1818250 shares per day over the past 10 days. A total of 25.47M shares are outstanding, with a floating share count of 22.43M. Insiders hold about 11.94% of the company’s shares, while institutions hold 27.66% stake in the company. Shares short for VYNE as of 1756425600 were 1336204 with a Short Ratio of 0.56, compared to 1753920000 on 2090114. Therefore, it implies a Short% of Shares Outstanding of 1336204 and a Short% of Float of 5.2800003.
Earnings Estimates
Its stock is currently analyzed by 2.0 different market analysts. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.89 and -$0.89 for the fiscal current year, implying an average EPS of -$0.89. EPS for the following year is -$1.1, with 1.0 analysts recommending between -$1.1 and -$1.1.
Revenue Estimates
According to 1 analysts, the current quarter’s revenue is expected to be $100k. It ranges from a high estimate of $100k to a low estimate of $100k. As of the current estimate, VYNE Therapeutics Inc’s year-ago sales were $121kFor the next quarter, 1 analysts are estimating revenue of $100k. There is a high estimate of $100k for the next quarter, whereas the lowest estimate is $100k.
